Loading...
60 favipiravir COVID-19 controlled studies, 30 RCTs
https://c19early.org/ameta.html
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+
Ruzhentsova (RCT) 6%
0.94 [0.78-1.14]
hosp.
3/112
2/56
Improvement, RR [CI] Treatment Control Ruzhentsova (RCT) 39%
0.61 [0.43-0.88]
no recov.
112 (n)
56 (n)
Ruzhentsova (RCT) 22%
0.78 [0.92-1.79]
viral+
112 (n)
56 (n)
Udwadia (RCT) 40%
0.60 [0.38-0.95]
recov. time
75 (n)
75 (n)
Udwadia (RCT) 29%
0.71 [0.46-1.10]
viral time
75 (n)
75 (n)
Sawanpanyalert 68%
0.32 [0.15-0.66]
progression
n/a
n/a
Holubar (DB RCT) 89%
0.11 [0.01-2.02]
hosp.
0/75
4/74
Holubar (DB RCT) 30%
0.70 [0.23-2.12]
ER visit
5/75
7/74
Holubar (DB RCT) -19%
1.19 [0.78-1.85]
no recov.
65 (n)
70 (n)
Holubar (DB RCT) -32%
1.32 [0.83-2.08]
viral+
59 (n)
57 (n)
Alattar (PSM) 33%
0.67 [0.28-1.61]
death
8/387
12/387
Alattar (PSM) -2%
1.02 [0.90-1.16]
no recov.
26/387
28/387
Alattar (PSM) -6%
1.06 [0.99-1.14]
recov. time
387 (n)
387 (n)
Alattar (PSM) 44%
0.56 [0.44-0.71]
viral+
78/387
139/387
Bosaeed (DB RCT) -619%
7.19 [0.38-138]
ICU
3/112
0/119
Bosaeed (DB RCT) -219%
3.19 [0.66-15.5]
hosp.
6/112
2/119
Bosaeed (DB RCT) -12%
1.12 [0.80-1.56]
no recov.
112 (n)
119 (n)
Bosaeed (DB RCT) -15%
1.15 [0.75-1.75]
viral+
112 (n)
119 (n)
FLARE
Lowe (DB RCT) -202%
3.02 [0.13-72.6]
ICU
1/59
0/60
FLARE
Lowe (DB RCT) -202%
3.02 [0.13-72.6]
hosp.
1/59
0/60
FLARE
Lowe (DB RCT) 28%
0.72 [0.44-0.98]
viral+
29/54
38/52
Adhikari (RCT) -40%
1.40 [0.57-3.44]
no improv.
10/38
6/32
Adhikari (RCT) -36%
1.36 [0.52-3.59]
no improv.
8/27
5/23
Adhikari (RCT) -64%
1.64 [0.18-15.3]
no improv.
2/11
1/9
Tsuzuki 13%
0.87 [0.52-1.46]
death
2,532 (n)
5,122 (n)
Tsuzuki -2%
1.02 [0.65-1.60]
ventilation
2,532 (n)
5,122 (n)
Tsuzuki 18%
0.82 [0.66-1.04]
progression
2,532 (n)
5,122 (n)
Qadir 97%
0.03 [0.00-0.47]
death
0/125
17/125
Qadir 60%
0.40 [0.23-0.71]
hosp.
14/125
35/125
Qadir 97%
0.03 [0.00-0.47]
no recov.
0/125
17/125
Qadir 71%
0.29 [0.17-0.50]
no recov.
14/125
48/125
Qadir 79%
0.21 [0.13-0.36]
no recov.
14/125
66/125
Qadir 71%
0.29 [0.22-0.40]
no recov.
32/125
109/125
Qadir 58%
0.42 [0.25-0.70]
recov. time
125 (n)
125 (n)
Usanma Koban 86%
0.14 [0.02-0.70]
viral+
47 (n)
79 (n)
Sirijatuphat (RCT) 64%
0.36 [0.20-0.64]
improv.
62 (n)
31 (n)
Sirijatuphat (RCT) 90%
0.10 [0.03-0.39]
improv.
62 (n)
31 (n)
Sirijatuphat (RCT) 43%
0.57 [0.23-1.43]
progression
8/62
7/31
Sirijatuphat (RCT) -4%
1.04 [0.63-1.72]
viral+
62 (n)
31 (n)
McMahon (RCT) -1%
1.01 [0.34-3.03]
oxygen
6/99
6/100
McMahon (RCT) -56%
1.56 [0.71-3.43]
hosp.
14/99
9/99
PRESECO
Golan (DB RCT) 67%
0.33 [0.01-8.12]
death
0/599
1/588
PRESECO
Golan (DB RCT) 2%
0.98 [0.43-2.25]
progression
11/599
11/588
PRESECO
Golan (DB RCT) 7%
0.93 [0.77-1.12]
progression
159/599
168/588
PRESECO
Golan (DB RCT) 4%
0.96 [0.71-1.29]
no recov.
73/599
75/588
PRESECO
Golan (DB RCT) 14%
0.86 [0.81-0.91]
viral time
140 (n)
132 (n)
Bruminhent -227%
3.27 [1.43-7.50]
progression
n/a
n/a
Chandiwana (RCT) -13%
1.13 [0.23-5.46]
progression
37 (n)
39 (n)
CT2
Chandiwana (RCT) -23%
1.23 [0.73-2.08]
recov. time
37 (n)
39 (n)
CT2
Chandiwana (RCT) -67%
1.67 [0.85-3.23]
viral+
27/37
25/38
CT2
Vaezi (DB RCT) -105%
2.05 [0.40-10.6]
hosp.
4/38
2/39
PLATCOV
Luvira (RCT) -6%
1.06 [0.69-1.63]
viral rate
116 (n)
132 (n)
Cai 69%
0.31 [0.10-0.96]
pneumonia
35 (n)
45 (n)
Cai 71%
0.29 [0.10-0.86]
viral+
35 (n)
45 (n)
Ivashchenko (RCT) 46%
0.54 [0.33-0.88]
viral+
15/40
14/20
Ivashchenko (RCT) 62%
0.38 [0.09-1.52]
viral+
3/40
4/20
Ivashchenko (RCT) -67%
1.67 [0.52-5.39]
no disch.
10/40
3/20
Ivashchenko (RCT) -300%
4.00 [0.20-79.6]
hosp.
2/40
0/20
Lou (RCT) -422%
5.22 [0.28-96.2]
ICU
2/9
0/10
Lou (RCT) 11%
0.89 [0.34-2.32]
no recov.
4/9
5/10
Lou (RCT) 14%
0.86 [0.58-1.30]
no recov.
7/9
9/10
Lou (RCT) -422%
5.22 [0.28-96.2]
viral+
2/9
0/10
Lou (RCT) -11%
1.11 [0.47-2.60]
viral+
5/9
5/10
Pushkar (RCT) 14%
0.86 [0.73-1.00]
no recov.
73/100
85/100
Pushkar (RCT) 33%
0.67 [0.54-0.82]
recov. time
100 (n)
100 (n)
Pushkar (RCT) 45%
0.55 [0.42-0.72]
no recov.
40/100
73/100
Pushkar (RCT) 20%
0.80 [0.64-1.00]
recov. time
100 (n)
100 (n)
Pushkar (RCT) 70%
0.30 [0.16-0.58]
no disch.
10/100
33/100
Pushkar (RCT) 27%
0.73 [0.63-0.86]
no recov.
66/100
90/100
Pushkar (RCT) 33%
0.67 [0.50-0.89]
pneumonia
40/100
60/100
Pushkar (RCT) 90%
0.10 [0.02-0.40]
viral+
2/100
21/100
Khamis (RCT) 15%
0.85 [0.28-2.59]
death
5/44
6/45
OT1 CT2
Khamis (RCT) -2%
1.02 [0.42-2.48]
ICU
8/44
8/45
OT1 CT2
Khamis (RCT) -10%
1.10 [0.60-1.99]
no recov.
15/44
14/45
OT1 CT2
Solaymani.. (RCT) -19%
1.19 [0.70-2.04]
death
26/190
21/183
OT1
Solaymani.. (RCT) -53%
1.53 [0.86-2.71]
ventilation
27/190
17/183
OT1
Solaymani.. (RCT) -19%
1.19 [0.73-1.94]
ICU
31/190
25/183
OT1
Zhao (RCT) 59%
0.41 [0.16-1.03]
viral+
7/36
9/19
Zhao (RCT) 52%
0.48 [0.25-0.91]
viral time
36 (n)
19 (n)
Aghajani 26%
0.74 [0.43-1.27]
death
40 (n)
951 (n)
Alamer -56%
1.56 [0.73-3.36]
death
12/233
21/223
Alamer 90%
0.10 [0.04-0.29]
ventilation
4/218
27/165
Alamer 49%
0.51 [0.41-0.64]
no disch.
221 (n)
201 (n)
Almoosa -42%
1.42 [0.90-2.25]
death
33/110
24/116
Almoosa -149%
2.49 [1.29-4.80]
death
26/110
11/116
Almoosa 62%
0.38 [0.13-1.17]
death
4/110
11/116
Almoosa -90%
1.90 [1.11-3.26]
ICU
110 (n)
116 (n)
Almoosa -11%
1.11 [0.96-1.29]
recov. time
110 (n)
116 (n)
Shinkai (SB RCT) 37%
0.63 [0.40-0.98]
imp. time
107 (n)
49 (n)
Shinkai (SB RCT) 59%
0.41 [0.18-0.93]
imp. time
47 (n)
13 (n)
Assiri (ICU) -79%
1.79 [0.33-8.02]
death
11/67
3/51
ICU patients
Kulzhanova 88%
0.12 [0.04-0.37]
no improv.
3/40
25/40
Kulzhanova 89%
0.11 [0.01-2.00]
no improv.
0/40
4/40
Kulzhanova 50%
0.50 [0.21-1.20]
viral+
6/40
12/40
Chen (RCT) -3%
1.03 [0.15-7.22]
ICU
2/116
2/120
OT1
Chen (RCT) 74%
0.26 [0.03-2.28]
resp. failure
1/116
4/120
OT1
Chen (RCT) 20%
0.80 [0.48-1.34]
oxygen
21/116
27/120
OT1
Chen (RCT) 70%
0.30 [0.10-0.87]
dyspnea
4/116
14/120
OT1
Chen (RCT) 10%
0.90 [0.45-1.80]
dyspnea
13/116
15/120
OT1
Chen (RCT) 20%
0.80 [0.60-1.08]
no recov.
45/116
58/120
OT1
Alotaibi 57%
0.43 [0.18-1.01]
death
244 (n)
193 (n)
OT1
Tabarsi (RCT) 30%
0.70 [0.17-2.88]
death
3/32
4/30
OT1
Tabarsi (RCT) 41%
0.59 [0.22-1.59]
ICU
5/32
8/30
OT1
Tabarsi (RCT) 6%
0.94 [0.72-1.23]
CT imp.
24/32
24/30
OT1
Tabarsi (RCT) 25%
0.75 [0.58-0.97]
hosp. time
32 (n)
30 (n)
OT1
FIGHT-COVID-19
Atipornwa.. (RCT) 23%
0.77 [0.35-1.67]
death
10/100
13/100
OT1 CT2
FIGHT-COVID-19
Atipornwa.. (RCT) 60%
0.40 [0.20-0.79]
progression
10/100
25/100
OT1 CT2
FIGHT-COVID-19
Atipornwa.. (RCT) 9%
0.91 [0.73-1.14]
viral time
50 (n)
50 (n)
OT1 CT2
FIGHT-COVID-19
Atipornwa.. (RCT) 9%
0.91 [0.75-1.10]
viral time
50 (n)
50 (n)
OT1 CT2
Damayanti 54%
0.46 [0.22-0.92]
no recov.
96 (n)
96 (n)
Shenoy (DB RCT) -29%
1.29 [0.60-2.77]
death
14/175
11/178
Shenoy (DB RCT) -33%
1.33 [0.67-2.66]
ventilation
17/175
13/178
Shenoy (DB RCT) -2%
1.02 [0.57-1.82]
ICU
20/175
20/178
Shenoy (DB RCT) -1%
1.01 [0.78-1.30]
no recov.
157 (n)
158 (n)
Shenoy (DB RCT) 6%
0.94 [0.75-1.18]
no recov.
175 (n)
178 (n)
Shenoy (DB RCT) 17%
0.83 [0.58-1.18]
no recov.
157 (n)
158 (n)
Shenoy (DB RCT) 32%
0.68 [0.50-0.93]
no recov.
175 (n)
178 (n)
Chuah (RCT) -1154%
12.54 [0.76-208]
death
5/250
0/250
Chuah (RCT) -20%
1.20 [0.36-3.97]
ventilation
6/250
5/250
Chuah (RCT) -9%
1.09 [0.49-2.31]
ICU
13/250
12/250
Finberg (RCT) -200%
3.00 [0.13-70.3]
death
1/25
0/25
Finberg (RCT) -200%
3.00 [0.13-70.3]
ventilation
1/25
0/25
Finberg (RCT) 58%
0.42 [0.16-1.10]
no recov.
25 (n)
25 (n)
Finberg (RCT) -46%
1.46 [0.45-4.81]
no recov.
25 (n)
25 (n)
Finberg (RCT) 47%
0.53 [0.29-0.98]
viral time
25 (n)
25 (n)
Al Mutair (ICU) 7%
0.93 [0.77-1.12]
death
119/269
128/269
ICU patients OT1
Al Mutair (ICU) -9%
1.09 [0.82-1.43]
ARDS
76/269
70/269
ICU patients OT1
Al Mutair (ICU) -34%
1.34 [1.13-1.59]
ICU
269 (n)
269 (n)
ICU patients OT1
Al Mutair (ICU) -37%
1.37 [1.14-1.64]
hosp. time
269 (n)
269 (n)
ICU patients OT1
Kurniyanto 48%
0.52 [0.22-1.25]
death
10/325
9/152
Cilli 38%
0.62 [0.24-1.63]
death
5/23
8/23
Al-Muhsen -263%
3.63 [1.06-12.4]
death
156 (n)
442 (n)
Al-Muhsen 41%
0.59 [0.47-0.75]
oxygen
52/156
248/442
Al-Muhsen -40%
1.40 [1.03-1.91]
hosp. time
156 (n)
442 (n)
Yulia 85%
0.15 [0.02-1.02]
death
432 (all patients)
Uyaroğlu (PSM) 67%
0.33 [0.01-7.96]
death
0/42
1/42
OT1
Uyaroğlu (PSM) -200%
3.00 [0.13-71.6]
ICU
1/42
0/42
OT1
Uyaroğlu (PSM) -11%
1.11 [0.24-5.08]
hosp. time
42 (n)
42 (n)
OT1
AlQahtani (RCT) -196%
2.96 [0.12-71.1]
death
1/54
0/52
AlQahtani (RCT) 76%
0.24 [0.03-2.08]
ICU
1/54
4/52
AlQahtani (RCT) -42%
1.42 [0.50-4.04]
no recov.
8/53
5/47
AlQahtani (RCT) 43%
0.57 [0.27-1.21]
viral+
8/40
14/40
Shinada 7%
0.93 [0.45-1.89]
hosp.
17 (n)
17 (n)
Shinada 55%
0.45 [0.21-0.96]
viral+
17 (n)
17 (n)
Hassaniazad (RCT) 68%
0.32 [0.07-1.48]
death
2/32
6/31
OT1
Hassaniazad (RCT) 3%
0.97 [0.06-14.8]
death
1/32
1/31
OT1
Hassaniazad (RCT) 35%
0.65 [0.20-2.07]
ICU
4/32
6/31
OT1
Hassaniazad (RCT) 25%
0.75 [0.51-1.10]
hosp. time
32 (n)
31 (n)
OT1
Hassaniazad (RCT) 18%
0.82 [0.62-1.08]
viral+
22/32
26/31
OT1
Hafez -3%
1.03 [0.68-1.56]
viral+
59 (n)
1,446 (n)
CT2
Hafez 59%
0.41 [0.15-1.15]
viral+
4 (n)
1,446 (n)
CT2
Rahman (DB RCT) 89%
0.11 [0.01-0.75]
no improv.
1/19
8/16
Rahman (DB RCT) 65%
0.35 [0.16-0.78]
no improv.
5/19
12/16
Rahman (DB RCT) 47%
0.53 [0.34-0.81]
no improv.
10/19
16/16
Rahman (DB RCT) 92%
0.08 [0.01-0.59]
viral+
1/25
12/25
Rahman (DB RCT) 62%
0.38 [0.18-0.80]
viral+
6/25
16/25
Rahman (DB RCT) 48%
0.52 [0.36-0.76]
viral+
13/25
25/25
Tehrani (RCT) 34%
0.66 [0.34-1.26]
hosp.
10/38
16/40
Tehrani (RCT) 80%
0.20 [0.01-4.12]
no recov.
0/38
2/40
Tehrani (RCT) 58%
0.42 [0.21-0.84]
no recov.
8/38
20/40
Tehrani (RCT) 47%
0.53 [0.05-5.57]
no recov.
1/38
2/40
Tehrani (RCT) 47%
0.53 [0.20-1.40]
no recov.
5/38
10/40
Tehrani (RCT) 66%
0.34 [0.01-8.07]
no recov.
0/38
1/40
Tehrani (RCT) 47%
0.53 [0.10-2.71]
no recov.
2/38
4/40
Tehrani (RCT) 30%
0.70 [0.45-1.10]
no recov.
16/38
24/40
Tehrani (RCT) 7%
0.93 [0.75-1.15]
no recov.
30/38
34/40
Tehrani (RCT) 21%
0.79 [0.30-2.06]
no recov.
6/38
8/40
Tehrani (RCT) 38%
0.62 [0.33-1.18]
no recov.
10/38
17/40
Abdulrahman (ICU) 3%
0.97 [0.81-1.18]
death
74/193
593/1,506
ICU patients
Acar Sevinc (ICU) 16%
0.84 [0.62-1.12]
death
57/85
12/15
ICU patients OT1
Acar Sevinc (ICU) 10%
0.90 [0.67-1.19]
ventilation
61/85
12/15
ICU patients OT1
Tawfik 96%
0.04 [0.00-0.26]
death
1/103
17/62
Tawfik 21%
0.79 [0.45-1.40]
ICU
21/103
16/62
Tawfik 16%
0.84 [0.80-0.88]
hosp. time
102 (n)
58 (n)
Babayigit -184%
2.84 [1.27-6.14]
ventilation
47/325
17/977
Babayigit -181%
2.81 [1.66-4.62]
ICU
75/325
35/969
Babayigit -100%
2.00 [1.33-3.02]
hosp. time
265 (n)
746 (n)
Behboodikhah 68%
0.32 [0.05-1.83]
death
95 (n)
2,079 (n)
PIONEER
Shah (RCT) 26%
0.74 [0.44-1.23]
death
26/251
34/248
PIONEER
Shah (RCT) 24%
0.76 [0.49-1.16]
ventilation
251 (n)
248 (n)
PIONEER
Shah (RCT) 6%
0.94 [0.79-1.12]
no recov.
251 (n)
248 (n)
Alosaimi (PSM) 80%
0.20 [0.01-4.03]
death
0/37
2/37
OT1
Alosaimi (PSM) -75%
1.75 [0.20-15.6]
hosp. time
37 (n)
37 (n)
OT1
Alosaimi (PSM) -40%
1.40 [0.21-9.26]
no disch.
37 (n)
37 (n)
OT1
Hartantri 76%
0.24 [0.11-0.54]
death
n/a
n/a
Hartantri 60%
0.40 [0.17-0.98]
death
n/a
n/a
Alshamrani (PSM) -14%
1.14 [0.96-1.35]
death
326/1,159
316/1,380
Alshamrani (PSM) -2%
1.02 [0.86-1.20]
progression
475/1,159
499/1,380
Alshamrani (PSM) -19%
1.19 [1.05-1.34]
ICU
668 (n)
633 (n)
Alshamrani (PSM) -29%
1.29 [1.11-1.50]
hosp. time
1,159 (n)
1,380 (n)
Favipiravir COVID-19 outcomes c19 early.org/a May 20231 OT: comparison with other treatment 2 CT: study uses combined treatment Favors favipiravir
Favors control
Please send us corrections, updates, or comments. Vaccines and
treatments are complementary. All practical, effective, and safe means should
be used based on risk/benefit analysis. No treatment, vaccine, or intervention
is 100% available and effective for all current and future variants. We do not
provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation.
FLCCC and
WCH
provide treatment protocols.
Submit
